---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000059"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:33:47.851227+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lisata Q2 net loss $4.7M, cash $22M; certepetide trials advancing with multiple data milestones ahead

## Summary
- Net loss of $4.7M vs $5.0M in Q2 2024; revenue of $70K from Catalent license fee.
- Cash, equivalents and securities total $22.0M; runway into Q4 2026 funds all active trials to next data milestone.
- ASCEND Phase 2b Cohort B showed positive PFS and ORR signal; final data expected late 2025.
- BOLSTER Phase 2a first-line CCA enrollment complete; topline data due Q4 2025.
- USPTO issued new composition-of-matter patent for certepetide (U.S. 12,351,653) extending protection to March 2040.

## SEC filing metadata
- accession: 0000320017-25-000059
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/0000320017-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/clbs-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000059
- JSON: https://secwatch.observer/filing/0000320017-25-000059.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.